STUTTGART, Germany I July 28, 2024 I Developed by Merck & Co., the blockbuster therapeutic antibody Keytruda (pembrolizumab) was first approved by the FDA in 2014 to treat several types of cancer. Since getting the initial green light, Keytruda has been approved for new and expanded uses, including melanoma, non-small cell lung cancer, head and neck cancer, classical Hodgkin lymphoma, urothelial carcinoma, microsatellite instability-high cancers, gastric cancer, cervical cancer, and primary mediastinal B-cell lymphoma. The very recent approval of Keytruda for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma marks the third endometrial carcinoma indication and the 40th indication overall for KEYTRUDA in the U.S.
Key patents of Keytruda will begin to expire in 2028, opening the door to biosimilar competition. In 2023, Keytruda posted global sales of US$ 25 bln which are already far higher than peak sales of anti-TNF antibody Humira in 2022 (US$ 21.6 bln) before declining to US$ 14.6 bln in 2023 due to biosimilar competition. No wonder, that the Keytruda biosimilar antibody pipeline has begun to grow and now already has more than eight Keytruda biosimilar candidates in clinical development.
Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. They are approved via stringent regulatory pathways in highly regulated markets (such as EU, US, Japan, Canada, Australia) based on proven similarity of the biosimilar with the originator biopharmaceutical reference product.
La Merie Publishing released its newest product reviewing the pipeline of drug candidates in research and development as biosimilar antibodies of Keytruda (pembrolizumab):
Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review
This product consists of:
- Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, territory of main competitor, indication(s) & R&D stage.
- Project History with link to source of information (press release, homepage, abstracts, presentations, annual reports etc).
- One-month online access to La Merie Publishing’s database for pembrolizumab (Keytruda) biosimilars (prerequisite: access to internet).
This product is delivered on the very same day by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day of order.
The report “Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/pembrolizumab-keytruda-biosimilar-antibody-pipeline-review/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing
Post Views: 5,207
STUTTGART, Germany I July 28, 2024 I Developed by Merck & Co., the blockbuster therapeutic antibody Keytruda (pembrolizumab) was first approved by the FDA in 2014 to treat several types of cancer. Since getting the initial green light, Keytruda has been approved for new and expanded uses, including melanoma, non-small cell lung cancer, head and neck cancer, classical Hodgkin lymphoma, urothelial carcinoma, microsatellite instability-high cancers, gastric cancer, cervical cancer, and primary mediastinal B-cell lymphoma. The very recent approval of Keytruda for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma marks the third endometrial carcinoma indication and the 40th indication overall for KEYTRUDA in the U.S.
Key patents of Keytruda will begin to expire in 2028, opening the door to biosimilar competition. In 2023, Keytruda posted global sales of US$ 25 bln which are already far higher than peak sales of anti-TNF antibody Humira in 2022 (US$ 21.6 bln) before declining to US$ 14.6 bln in 2023 due to biosimilar competition. No wonder, that the Keytruda biosimilar antibody pipeline has begun to grow and now already has more than eight Keytruda biosimilar candidates in clinical development.
Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. They are approved via stringent regulatory pathways in highly regulated markets (such as EU, US, Japan, Canada, Australia) based on proven similarity of the biosimilar with the originator biopharmaceutical reference product.
La Merie Publishing released its newest product reviewing the pipeline of drug candidates in research and development as biosimilar antibodies of Keytruda (pembrolizumab):
Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review
This product consists of:
- Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, territory of main competitor, indication(s) & R&D stage.
- Project History with link to source of information (press release, homepage, abstracts, presentations, annual reports etc).
- One-month online access to La Merie Publishing’s database for pembrolizumab (Keytruda) biosimilars (prerequisite: access to internet).
This product is delivered on the very same day by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day of order.
The report “Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/pembrolizumab-keytruda-biosimilar-antibody-pipeline-review/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing
Post Views: 5,207
